Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation in the Japanese healthcare setting

References

• Lip GYH, Brechin CM, Lane DA. The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. Chest. 2012;142(6):1489–1498.
   PubMed Web of Science ®Google Scholar
• Wolf PA, Dawber TR, Thomas HE, et al. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology. 1978;28(10):973–977.
   PubMed Web of Science ®Google Scholar
• Okumura KI, Atarashi H, Yamashita H, et al. J. Rhythm Registry Investigators. Validation of CHA2DS2-VASc and HAS-BLED scores in Japanese patients with nonvalvular atrial fibrillation: an analysis of the J-RHYTHM Registry. Circ J. 2014;78(7):1593–1599.
   PubMed Web of Science ®Google Scholar
• JCS. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2013). Circ J. 2014;78(8):1997–2021.
   PubMed Web of Science ®Google Scholar
• ROCKET AF study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J. 2010;159(3):340–347.e1.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891.
   PubMed Web of Science ®Google Scholar
• Hori M, Matsumoto M, Tanahashi N, et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF study. Circ J. 2012;76(9):2104–2111.
   PubMed Web of Science ®Google Scholar
• Morais J, Aguiar C, McLeod E, et al. Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting. Rev Port Cardiol. 2014;33(9):535–544.
   PubMedGoogle Scholar
• Kleintjens J, Li X, Simoens S, et al. Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting. Pharmacoeconomics. 2013;31(10):909–918.
   PubMed Web of Science ®Google Scholar
• Harrington AR, Armstrong EP, Nolan PE, et al. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke. 2013;44(6):1676–1681.
   PubMed Web of Science ®Google Scholar
• Lee S, Anglade MW, Pham D, et al. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Am J Cardiol. 2012;110(6):845–851.
   PubMed Web of Science ®Google Scholar
• Rognoni C, Marchetti M, Quaglini S, et al. Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis. Clin Drug Investig. 2014;34(1):9–17.
   PubMed Web of Science ®Google Scholar
• Lanitis T, Cotté FE, Gaudin AF, et al. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin. J Med Econ. 2014;17(8):587–598.
   PubMedGoogle Scholar
• Wisloff T, Hagen G, Klemp M. Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation. Pharmacoeconomics. 2014;32(6):601–612.
   PubMed Web of Science ®Google Scholar
• Wang Y, Xie F, Kong MC, et al. Cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for stroke prevention in patients with atrial fibrillation. Cardiovasc Drugs Ther. 2014;28(6):575–585.
   PubMed Web of Science ®Google Scholar
• Mensch A, Stock S, Stollenwerk B, et al. Cost effectiveness of rivaroxaban for stroke prevention in German patients with atrial fibrillation. Pharmacoeconomics. 2015;33(3):271–283.
   PubMed Web of Science ®Google Scholar
• Kourlaba G, Maniadakis N, Andrikopoulos G, et al. Economic evaluation of rivaroxaban in stroke prevention for patients with atrial fibrillation in Greece. Cost Eff Resour Alloc. 2014;12(1):5.
   PubMedGoogle Scholar
• Research Group on Economic Evaluation for Japanese Public Medical Benefits. Guideline for economic evaluation of healthcare technologies in Japan. Tokyo; 2016. Version 2.0 approved by CSIMC on 20th February 2019. [cited 2019 Oct 10]. Available from: https://c2h.niph.go.jp/en/tools/guideline/index.html
   Google Scholar
• Kimura K, Minematsu K, Yamaguchi T. Atrial fibrillation as a predictive factor for severe stroke and early death in 15,831 patients with acute ischaemic stroke. J Neurol Neurosurg Psychiatry. 2005;76(5):679–683.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Whitehead A. Borrowing strength from external trials in a meta-analysis. Statist Med. 1996;15(24):2733–2749.
   PubMed Web of Science ®Google Scholar
• Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Statist Med. 2004;23(20):3105–3124.
   PubMed Web of Science ®Google Scholar
• Dias S, Welton NJ, Caldwell DM, et al. Checking consistency in mixed treatment comparison meta-analysis. Statist Med. 2010;29(7-8):932–944.
   PubMed Web of Science ®Google Scholar
• Dias S, Welton NJ, Sutton AJ, et al. NICE decision support unit technical support documents. In: NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. London: National Institute for Health and Care Excellence (NICE); 2014.
   Google Scholar
• Ministry of Health, Labour, and Welfare. 22nd Life Tables. 2015. [cited 2018 Oct 10]. Available from: http://www.mhlw.go.jp/toukei/list/list54-57.html.
   Google Scholar
• Yakka Search. Yakka Search Version 3.0. 2017. [cited 2017 Oct 16]. Available from: http://yakka-search.com/
   Google Scholar
• Pharmaceuticals and Medical Devices Agency. Search of package inserts. 2017. [cited 2017 Oct 16]. Available from: http://www.info.pmda.go.jp/psearch/html/menu_tenpu_base.html
   Google Scholar
• Kamae IH, Koretsune Y, Tanahashi Y, et al. Cost-effectiveness analysis of apixaban against warfarin for stroke prevention in patients with nonvalvular atrial fibrillation in Japan. Clin Therap. 2015;37(12):2837–2851.
   PubMed Web of Science ®Google Scholar
• Hattori N, Hirayama T, Katayama Y. Medical care for chronic-phase stroke in Japan. Neurol Med Chir. 2012;52(4):175–180.
   PubMed Web of Science ®Google Scholar
• Ministry Of Health, Labour, and Family Welfare. Revision net rate FY2014. 2013. [cited 2018 Oct 16]. Available from: http://www.mhlw.go.jp/file/04-Houdouhappyou-12404000-Hokenkyoku-Iryouka/0000033791.pdf.
   Google Scholar
• Ministry Of Health, Labour, and Family Welfare. Revision net rate FY2016. 2015. [cited 2018 Oct 16]. Available from: http://www.mhlw.go.jp/file/04-Houdouhappyou-12401000-Hokenkyoku-Soumuka/0000107690.pdf.
   Google Scholar
• Hori M. 非弁膜症性心房細動患者の脳卒中予防に対するダビガトランエテキシラートの医療経済分析' [Health economic evaluation of dabigatran etexilate for stroke prevention in patients with non-valvular atrial fibrillation]. Pharma Med. 2011;29:151–164.
   Google Scholar
• Okumura K. Estimation of event cost reduction by administration of apixaban to patients with non-valvular atrial fibrillation. 医薬ジャーナル (0287-4741). 2014;50:993–1003.
   Google Scholar
• Kobayashi S, Ohgushi Y. Japanese Stroke Databank 2015. Tokyo, Japan: Nakayama Shoten Co. Ltd; 2015 (in Japanese).
   Google Scholar
• BayerPlc. Submission to National Institute for Health and Clinical Excellence: Single Technology Appraisal (STA) of Rivaroxaban (Xarelto®). 2011. [cited 2019 June 28]. Available from: https://www.nice.org.uk/guidance/ta256/documents/atrial-fibrillation-stroke-prevention-rivaroxaban-bayer4.
   Google Scholar
• Hoit BD, Gilpin EA, Henning H, et al. Myocardial infarction in young patients: an analysis by age subsets. Circulation. 1986;74(4):712–721.
   PubMedGoogle Scholar
• Shirobon. Shirobon Net. 2016. [cited 2017 Oct 16]. Available from: http://shirobon.net/.
   Google Scholar
• Takashima N, Arima H, Kita Y, et al. Incidence, management and short-term outcome of stroke in a general population of 1.4 million Japanese-Shiga Stroke Registry. Circ J. 2017;81(11):1636–1646.
   PubMed Web of Science ®Google Scholar
• Sorensen SV, Kansal AR, Connolly S, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost. 2011;105(5):908–919.
   PubMed Web of Science ®Google Scholar
• Tanihata S, Nishigaki K, Kawasaki M, et al. Outcomes of patients with stable low-risk coronary artery disease receiving medical- and PCI-preceding therapies in Japan: J-SAP study 1-1. Circ J. 2006;70(4):365–369.
   PubMed Web of Science ®Google Scholar
• Evans E, Imanaka Y, Sekimoto M, et al. Risk adjusted resource utilization for AMI patients treated in Japanese hospitals. Health Econ. 2007;16(4):347–359.
   PubMed Web of Science ®Google Scholar
• Shiroiwa T, Fukuda T, Ikeda S, et al. Japanese population norms for preference-based measures: EQ-5D-3L, EQ-5D-5L, and SF-6D. Qual Life Res. 2016;25(3):707–719.
   PubMed Web of Science ®Google Scholar
• Dorian P, Kongnakorn T, Phatak H, et al. Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation. Eur Heart J. 2014;35(28):1897–1906.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Kongnakorn T, Phatak H, et al. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation. Clin Ther. 2014;36(2):192–210.e20.
   PubMed Web of Science ®Google Scholar
• Hallan S, Asberg A, Indredavik B, et al. Quality of life after cerebrovascular stroke: a systematic study of patients' preferences for different functional outcomes. J Intern Med. 1999;246(3):309–316.
   PubMed Web of Science ®Google Scholar
• Sanders GD, Hlatky MA, Every NR, et al. Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. Ann Intern Med. 2001;135(10):870–883.
   PubMed Web of Science ®Google Scholar